Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/16780
Title: Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis
Authors: Wirongrong Chierakul
Siriluck Anunnatsiri
Jennifer M. Short
Bina Maharjan
Piroon Mootsikapun
Andrew J.H. Simpson
Direk Limmathurotsakul
Allen C. Cheng
Kasia Stepniewska
Paul N. Newton
Wipada Chaowagul
Nicholas J. White
Sharon J. Peacock
Nicholas P. Day
Ploenchan Chetchotisakd
Mahidol University
Khon Kaen University
Sappasitthiprasong Hospital
Nuffield Department of Clinical Medicine
Keywords: Medicine
Issue Date: 15-Oct-2005
Citation: Clinical Infectious Diseases. Vol.41, No.8 (2005), 1105-1113
Abstract: Background. Two antibiotic regimens are used commonly in Thailand for the initial treatment of severe melioidosis: ceftazidime in combination with trimethoprim-sulfamethoxazole (TMP-SMX) and ceftazidime monotherapy. It is not known whether TMP-SMX provides an additional benefit. Methods. Two prospective, randomized trials that compared these regimens for patients presenting with acute severe melioidosis were started independently at tertiary care hospitals in Ubon Ratchathani and Khon Kaen (in northeastern Thailand), and the results were analyzed together as a prospective, individual-patient data meta-analysis. The primary end point was in-hospital mortality rate. Results. The in-hospital mortality rate among all enrolled patients (n = 449) was not significantly different between those randomized to ceftazidime alone (25.1%; 56 of 223 subjects) and those randomized to ceftazidime with TMP-SMX (26.6%; 60 of 226 subjects; odds ratio [OR], 1.08; 95% confidence interval [CI], 0.7-1.7; stratified P = .73). Of the 241 patients with culture-confirmed melioidosis, 51 (21.2%) died. Of these 241 patients, 31 (12.9%) died ≥48 h after the time of study entry. Among patients with melioidosis, there was no difference in death rate between the 2 treatment groups for either all deaths (OR, 0.88; 95% CI, 0.48-1.6; stratified P = .70) or for deaths that occurred ≥48 h after hospital admission (OR, 0.88; 95% CI, 0.41-1.9; stratified P = .73). Conditional logistic regression analysis revealed that bacteremia, respiratory failure, and renal failure were independently associated with death and treatment failure. Drug regimens were not associated with death or treatment failure in this model. Conclusion. We conclude that the addition of TMP-SMX to ceftazidime therapy during initial treatment of severe melioidosis does not reduce the acute mortality rate. © 2005 by the Infectious Diseases Society of America. All rights reserved.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=26444505890&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/16780
ISSN: 10584838
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.